Compare DCBO & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | BBNX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.5M | 613.7M |
| IPO Year | N/A | N/A |
| Metric | DCBO | BBNX |
|---|---|---|
| Price | $16.26 | $13.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $33.78 | $27.08 |
| AVG Volume (30 Days) | 242.5K | ★ 997.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.67 | $35.03 |
| Revenue Next Year | $7.43 | $33.24 |
| P/E Ratio | $24.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.05 | $8.89 |
| 52 Week High | $42.53 | $32.71 |
| Indicator | DCBO | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 24.75 | 32.52 |
| Support Level | $18.50 | $13.25 |
| Resistance Level | $19.15 | $15.53 |
| Average True Range (ATR) | 0.82 | 1.16 |
| MACD | -0.09 | 0.47 |
| Stochastic Oscillator | 4.95 | 54.88 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.